Annual Report for the financial year 2024-2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx Ltd has submitted its 53rd Annual Report for FY 2024-25 to BSE. The Board has recommended a dividend of ₹4 per equity share (40%) on shares of ₹10 face value, subject to shareholder approval at the AGM on 26th September 2025. In the Chairman's message, the company highlighted that its TRUPCR molecular diagnostics portfolio now reaches over 70 countries, with strong performance from its UK subsidiary TRUPCR Europe Limited. A key milestone was the acquisition of Belgium-based Coris BioConcept SRL, strengthening its rapid diagnostics (lateral flow) offering alongside its PCR portfolio. The AGM notice also seeks shareholder approval for re-appointment of Mr. Dhirendra Dubey as Chairman-cum-Managing Director for another five years, revision of his and CFO Mr. Nikhil Kuber Dubey's remuneration, appointment of a new Independent Director, and a new Secretarial Auditor for a five-year term.
The filing is routine (annual report submission) but signals a profitable year supporting a dividend payout and confirms continued international expansion plus a strategic European acquisition. Shareholders should note the pending AGM resolutions on director remuneration and re-appointments, which require their voting approval.